Clinical trial
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
NCT02110706 · Yale University, Other · Completed
Key facts
| NCT number | NCT02110706 |
|---|---|
| Title | BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis |
| Official title | B Cell Targeted Treatment In Myasthenia Gravis (BeatMG): A Phase II Trial of Rituximab In Myasthenia Gravis |
| Lead sponsor | Yale University, Other |
| Collaborators | National Institute of Neurological Disorders and Stroke (NINDS) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myasthenia Gravis |
| Intervention type | Drug |
| Interventions | Rituximab, Placebo |
| Enrollment | 52 |
| Start date | May 1, 2014 |
| Primary completion | Jul 1, 2017 |
| Completion | May 1, 2018 |
| First posted | Apr 10, 2014 |
| Last update posted | Mar 6, 2020 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: